Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 delafloxacin versus moxifloxacin for community-acquired bacterial pneumonia
2015-003026-14Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Delafloxacin IV to oral with Moxifloxacin IV to oral comparator (2 arms). Primary endpoint: Early Clinical Response. Started Dec 2015; status: completed.
02
Drugs
delafloxacinmoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2015-003026-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003026-14.